News

Songbirds Could Be Used as Valuable Tool to Study Brain Neurodegeneration, Huntington’s Disease

In a recent paper published in Nature Neuroscience journal entitled “Human mutant huntingtin disrupts vocal learning in transgenic songbirds“, Rockefeller University researchers reported that songbirds could be used as new tool to study Huntington’s disease (HD), providing a more complete understanding of the mechanisms underlying brain neurodegeneration.

Cloud Pharmaceuticals and THERAMetrics Partner to Develop Treatments for Orphan CNS Diseases

Cloud-based drug design and development company, Cloud Pharmaceuticals, Inc., recently announced it has signed with THERAMetrics holding AG to collaborate on breakthrough treatments for orphan central nervous system (CNS) diseases and other indications. This strategic collaboration has as its primary points of interest Huntington’s disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy…

Rich Club Brain Regions May Hold Clues to Huntington’s Disease

New research out of London has identified specific, highly connected brain regions, known as “rich club brain regions” that may be vulnerable in Huntington’s disease and possibly in other diseases in which there is progressive deterioration of brain cells (neurodegenerative diseases). The article, titled “Selective vulnerability of Rich…

Bioinformatics Unlocks Mechanisms of Disease Progression

Bioinformatics, a field that enables powerful analysis of large amounts of data, is being applied to Huntington’s disease to find potential candidate molecules that play a role in pathogenesis. Researchers have conducted high throughput screens of genetic information, and this information is now being deciphered by different computer programs to…

Sangamo and Shire Amend Contract to Expedite Development of ZFP Therapeutics for Huntington’s Disease

Sangamo BioSciences, Inc., a leader in therapeutic genome editing, recently announced it has agreed to amend its January 2012 collaboration and licensing agreement with Shire to accelerate the development of ZFP Therapeutics geared towards treated hemophilia A and B and Huntington’s disease. This agreement follows the companies’ mutual decision to refocus their research…